Condition
Microvascular Rarefaction
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05464849Completed
Evaluation of Systemic Microvascular Reactivity in Patients With Resistant Hypertension
NCT05728047CompletedPrimary
Evaluation of Systemic Microcirculation of Patients Undergoing Heart Valve Surgery
NCT04406545Completed
Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of COVID-19.
Showing all 3 trials